BCM
MLYS icon

BlueCrest Capital Management’s Mineralys Therapeutics MLYS Stock Holding History

BlueCrest Capital Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.3M Buy
+85,157
New +$2.34M 0.08% 167

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlueCrest Capital Management's MLYS Position: Q2 2026 in Review

BlueCrest Capital Management opened a new position in Mineralys Therapeutics (MLYS) in Q2 2026: 85,157 shares worth $2.3M. The stake represents 0.08% of the portfolio and ranks #167 among its holdings.

224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • BlueCrest Capital Management held 85,157 shares of Mineralys Therapeutics worth $2.3M as of Q2 2026.
  • Mineralys Therapeutics was a new BlueCrest Capital Management position in Q2 2026.
  • Mineralys Therapeutics made up 0.08% of BlueCrest Capital Management's portfolio in Q2 2026, its #167 holding.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on BlueCrest Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.